Liver Cirrhosis Treatment Market Research Report Information By Treatment (Antibiotics, Immunosuppressants) and End-User (Hospitals and Clinics, Research and Academic Institutes) - Forecast to 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT

6.1. Overview

6.2. Antibiotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Immunosuppressants

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL LIVER CIRRHOSIS TREATMENT MARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL LIVER CIRRHOSIS TREATMENT MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Liver Cirrhosis Treatment Market

9.5. Competitive Benchmarking

9.6. Leading Players in terms of Number of Developments in the Global Liver Cirrhosis Treatment Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2020

9.8.2. Major Players R&D Expenditure 2020

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Pfizer, Inc.

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Merck & Co., Inc.

10.2.1. Company Overview

10.2.2. Product Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Novartis AG

10.3.1. Company Overview

10.3.2. Product Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. F. Hoffmann-La Roche Ltd

10.4.1. Company Overview

10.4.2. Product Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Takeda Pharmaceutical Company Limited

10.5.1. Company Overview

10.5.2. Product Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Gilead Sciences, Inc.

10.6.1. Company Overview

10.6.2. Product Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. AstraZeneca

10.7.1. Company Overview

10.7.2. Product Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Bayer AG

10.8.1. Company Overview

10.8.2. Product Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Sanofi

10.9.1. Company Overview

10.9.2. Product Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Shionogi Inc.

10.10.1. Company Overview

10.10.2. Product Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Promethera

10.11.1. Company Overview

10.11.2. Product Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Others

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 NORTH AMERICA: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 US: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 US: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 CANADA: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 11 CANADA: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 LATIN AMERICA: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 13 LATIN AMERICA: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 EUROPE: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 EUROPE: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 WESTERN EUROPE: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 17 WESTERN EUROPE: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 18 EASTERN EUROPE: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 19 EASTERN EUROPE: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: LIVER CIRRHOSIS TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: LIVER CIRRHOSIS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL LIVER CIRRHOSIS TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL LIVER CIRRHOSIS TREATMENT MARKET

FIGURE 4 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 5 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: LIVER CIRRHOSIS TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 8 EUROPE: LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 WESTERN EUROPE: LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 ASIA-PACIFIC: LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 MIDDLE EAST & AFRICA: LIVER CIRRHOSIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 GLOBAL LIVER CIRRHOSIS TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 PFIZER, INC..: KEY FINANCIALS

FIGURE 14 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 15 PFIZER, INC.: REGIONAL REVENUE

FIGURE 16 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 17 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 18 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 19 NOVARTIS AG: KEY FINANCIALS

FIGURE 20 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 21 NOVARTIS AG: REGIONAL REVENUE

FIGURE 22 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 24 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 25 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY FINANCIALS

FIGURE 26 TAKEDA PHARMACEUTICAL COMPANY LIMITED: SEGMENTAL REVENUE

FIGURE 27 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGIONAL REVENUE

FIGURE 28 GILEAD SCIENCES, INC.: KEY FINANCIALS

FIGURE 29 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE

FIGURE 30 GILEAD SCIENCES, INC.: REGIONAL REVENUE

FIGURE 31 ASTRAZENECA: KEY FINANCIALS

FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 33 ASTRAZENECA: REGIONAL REVENUE

FIGURE 34 BAYER AG: KEY FINANCIALS

FIGURE 35 BAYER AG: SEGMENTAL REVENUE

FIGURE 36 BAYER AG: REGIONAL REVENUE

FIGURE 37 SANOFI: KEY FINANCIALS

FIGURE 38 SANOFI: SEGMENTAL REVENUE

FIGURE 39 SANOFI: REGIONAL REVENUE

FIGURE 40 SHIONOGI INC.: KEY FINANCIALS

FIGURE 41 SHIONOGI INC.: SEGMENTAL REVENUE

FIGURE 42 SHIONOGI INC.: REGIONAL REVENUE

FIGURE 43 PROMETHERA: KEY FINANCIALS

FIGURE 44 PROMETHERA: SEGMENTAL REVENUE

FIGURE 45 PROMETHERA: REGIONAL REVENUE